Get the Stockscreener App
0.6709
6.21%
-0.0477
Klotho Neurosciences Inc stock is traded at $0.6709, with a volume of 1.30M.
It is down -6.21% in the last 24 hours and down -43.83% over the past month.
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
See More
Previous Close:
$0.7186
Open:
$0.71
24h Volume:
1.30M
Relative Volume:
0.04
Market Cap:
$30.86M
Revenue:
-
Net Income/Loss:
$-7.71M
P/E Ratio:
-8.3863
EPS:
-0.08
Net Cash Flow:
$-4.09M
1W Performance:
-13.48%
1M Performance:
-43.83%
6M Performance:
+75.75%
1Y Performance:
+0.00%
1-Day Range:
$0.6601
$0.75
1-Week Range:
$0.6601
$0.95
52-Week Range:
$0.1135
$3.9099
Klotho Neurosciences Inc Stock (KLTO) Company Profile
Name
Klotho Neurosciences Inc
Sector
Industry
Phone
646-916-5315
Address
1115 BROADWAY, NEW YORK
Compare KLTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KLTO
Klotho Neurosciences Inc
|
0.67 | 28.70M | 0 | -7.71M | -4.09M | -0.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.06 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.03 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
466.80 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
662.25 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
314.36 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Klotho Neurosciences Inc Stock (KLTO) Latest News
Klotho Neurosciences Inc. Sees Spike in Bullish Option Flow2025 Geopolitical Influence & Weekly Chart Analysis and Guides - beatles.ru
Published on: 2025-08-20 17:03:50 - beatles.ru
Custom watchlist performance reports with Klotho Neurosciences Inc.Market Volume Summary & Weekly High Conviction Ideas - Newser
What recovery options are there for Klotho Neurosciences Inc. Equity WarrantBreakout Watch & Risk Adjusted Swing Trade Ideas - Newser
What makes Klotho Neurosciences Inc. stock price move sharplyMarket Sentiment Review & Weekly Return Optimization Plans - Newser
Klotho Neurosciences advances ALS treatment candidate toward clinical trials By Investing.com - Investing.com Nigeria
Klotho Neurosciences shares fall 2.91% intraday despite positive shareholder update on partnerships and regulatory progress. - AInvest
Klotho Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Klotho Neurosciences advances ALS treatment candidate toward clinical trials - Investing.com
$8B Market Opportunity: Klotho Neurosciences Advances Revolutionary ALS Treatment with FDA Recognition - Stock Titan
Klotho Neurosciences, Inc. SEC 10-Q Report - TradingView
Analyzing drawdowns of Klotho Neurosciences Inc. with statistical toolsLayoff News & Community Verified Watchlist Alerts - Newser
What moving averages say about Klotho Neurosciences Inc. Equity WarrantJuly 2025 Market Mood & High Accuracy Trade Signal Alerts - Newser
Earnings visualization tools for Klotho Neurosciences Inc. Equity WarrantTrade Ideas & Detailed Earnings Play Alerts - Newser
Is Klotho Neurosciences Inc. Equity Warrant forming a breakout patternQuarterly Market Summary & Detailed Earnings Play Strategies - 선데이타임즈
What MACD signals say about Klotho Neurosciences Inc. Equity WarrantMarket Movers & Low Drawdown Momentum Trade Ideas - Newser
Why Klotho Neurosciences Inc. Equity Warrant stock attracts strong analyst attentionPortfolio Update Report & Real-Time Chart Pattern Alerts - Newser
Using portfolio simulators with Klotho Neurosciences Inc. Equity Warrant included2025 Key Lessons & Capital Efficiency Focused Strategies - Newser
Short interest data insights for Klotho Neurosciences Inc. Equity Warrant2025 Retail Activity & Free Real-Time Market Sentiment Alerts - Newser
What high frequency data says about Klotho Neurosciences Inc.2025 Market WrapUp & Daily Profit Maximizing Trade Tips - Newser
Buy Signal for Klotho Neurosciences Inc. Stock Key Technical Indicators to WatchWeekly Risk Report & Consistent Profit Alerts - Newser
Klotho Neurosciences regains full compliance with Nasdaq listing standards - MSN
Published on: 2025-08-16 20:37:12 - metal.it
Is Klotho Neurosciences Inc. currently under institutional pressureJuly 2025 Institutional & Consistent Growth Stock Picks - newsyoung.net
Exit strategy if you’re trapped in Klotho Neurosciences Inc.Weekly Market Summary & Real-Time Buy Signal Alerts - Newser
Klotho Neurosciences KLTO Q2 2025 Earnings Preview Downside Likely as Revenue Challenges Persist - AInvest
Using data filters to optimize entry into Klotho Neurosciences Inc. Equity Warrant2025 Fundamental Recap & Expert Curated Trade Setup Alerts - Newser
Published on: 2025-08-15 02:11:50 - Newser
Using flow based indicators on Klotho Neurosciences Inc. Equity WarrantPortfolio Value Report & AI Powered Market Trend Analysis - Newser
Klotho Neurosciences Delays Quarterly Report Filing - MSN
Will Klotho Neurosciences Inc. Recover After Recent Decline2025 Investor Takeaways & Community Driven Trade Alerts - mustnews.co.kr
Klotho Neurosciences Partners with AAVnerGene for Gene Therapy - MSN
Is Klotho Neurosciences Inc. Equity Warrant benefiting from innovation trendsJuly 2025 Patterns & AI Optimized Trading Strategy Guides - 선데이타임즈
Jocasta Neuroscience Lands $35 Million Series A to Advance Longevity Protein Program for Managing Cognitive Impairment - BioSpace
Klotho Neurosciences shares rise 2.85% premarket after initiating manufacturing of KLTO-202 gene therapy. - AInvest
Klotho Neurosciences shares fall 3.10% after-hours after initiating manufacturing of KLTO-202 gene therapy. - AInvest
Klotho Neurosciences initiates manufacturing of gene therapy candidate By Investing.com - Investing.com Nigeria
Klotho Neurosciences initiates manufacturing of gene therapy candidate - Investing.com
Klotho Neurosciences and AAVnerGene: A Strategic Alliance to Revolutionize Gene Therapy Manufacturing - AInvest
Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology - StreetInsider
Klotho Launches Revolutionary Gene Therapy Manufacturing Using AAVone Platform | KLTO Stock News - Stock Titan
FDA grants orphan drug designation to INc-developed gene therapy for ALS - UAB Barcelona
Options Data Show Bullish Bias in Klotho Neurosciences Inc. Equity WarrantStable Entry High Return Opportunities in Focus - beatles.ru
Is It Too Early to Call Recovery in Klotho Neurosciences Inc.Low Risk Swing Trade Opportunities Identified - metal.it
When is the best time to exit Klotho Neurosciences Inc.Daily Breakout List with Smart Filters - Newser
Why is Klotho Neurosciences Inc. stock attracting strong analyst attentionHigh-yield growth strategies - Jammu Links News
How strong is Klotho Neurosciences Inc. Equity Warrant company’s balance sheetBreakneck growth rates - Jammu Links News
Will earnings trigger a reversal in Klotho Neurosciences Inc. Equity WarrantEntry Timing with Downside Risk Analysis - Newser
What analysts say about Klotho Neurosciences Inc. Equity Warrant stockGet daily updates on the hottest stocks - Jammu Links News
How does Klotho Neurosciences Inc. compare to its industry peersFree Popular Stock Recommendations - Jammu Links News
How many analysts rate Klotho Neurosciences Inc. Equity Warrant as a “Buy”Unbelievable profit margins - Jammu Links News
Klotho Neurosciences Inc Stock (KLTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.33%
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):